HAART in HIV-1-infected individuals has a broad spectrum of clinical outcomes. In the
majority of patients, plasma viral load becomes undetectable and CD4+ T-cells increase …

Background. Sustained suppression of the human immunodeficiency virus (HIV) type 1 RNA
load with the use of highly active antiretroviral therapy (HAART) results in immunologic …

HIV infection results in CD4+ T cell deficiency, but efficient combination antiretroviral therapy
(c-ART) restores T cells and decreases morbidity and mortality. However, immune …

HAART has significantly changed the natural history of HIV infection: patients receiving
antiretrovirals are usually able to control viremia, even though not all virological responders …

Objectives: To determine the clinical and immunological outcomes of a cohort of HIV-
infected patients receiving antiretroviral therapy. Design: Retrospective study of …

Objective: CD4 cell count changes in therapy-naive patients were investigated during 7
years of highly active antiretroviral therapy (HAART) in an observational cohort. Methods …

Background: Few data are available on the long-term immunologic response to antiretroviral
therapy (ART) in resource-limited settings, where ART is being rapidly scaled up using a …

Background The unique health needs of a growing older adult population infected with
human immunodeficiency virus (HIV) require study, especially in terms of the response to …

Background Human immunodeficiency virus/Acquired immunodeficiency syndrome
associated morbidity and mortality has reduced significantly since the introduction of highly …

Background: Low CD4+ increases risk for both AIDS-and non-AIDS-related morbidity and
mortality. The magnitude of CD4+ recovery early after initial antiretroviral therapy (ART) is …